Related Experiment Video
Updated: Sep 10, 2025
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.5K
Association Between ABCG2 Polymorphism and Statin-Induced Adverse Events: A Meta-Analysis
Da Hoon Lee1, Hae Ji Shin2, Beom Yoon2
1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
Cardiovascular Toxicology
|August 23, 2025
Summary
The ABCG2 rs2231142 gene variant is linked to increased statin toxicity, including muscle and liver issues. This finding highlights the need for personalized medicine in statin therapy.
Area of Science:
- Pharmacogenomics
- Cardiovascular Disease Research
- Drug Metabolism
Background:
- Statins are crucial for cardiovascular disease prevention but can cause adverse reactions.
- The ATP-binding cassette subfamily G member 2 (ABCG2) gene influences drug metabolism.
- The ABCG2 rs2231142 polymorphism's role in statin toxicity requires clarification.
Purpose of the Study:
- To systematically review and meta-analyze the association between the ABCG2 rs2231142 polymorphism and statin-induced toxicity.
- To clarify inconclusive findings from previous investigations.
Main Methods:
- Comprehensive literature search identifying seven eligible studies.
- Rigorous data extraction and quality assessment of included studies.
- Meta-analysis to determine the overall association and risk ratios.
Main Results:
- A significant association was found between the ABCG2 rs2231142 polymorphism and increased overall statin-induced toxicity.
- Specific risks identified for muscular (OR=2.6) and hepatic (OR=2.7) toxicity.
- The polymorphism impacts statin metabolism and pharmacokinetics.
Conclusions:
- The ABCG2 rs2231142 polymorphism is a potential risk factor for statin-induced toxicity.
- Findings support the importance of personalized treatment strategies for statin therapy.
- Further research into ABCG2's role in adverse drug reactions is warranted.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:19Pharmacovigilance
989
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
989
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33